ABSTRACT
Peripheral artery disease is growing in global prevalence. Its most severe form, critical limb ischemia (CLI), is associated with high rates of limb loss, morbidity, and mortality. Neovascularization is the cornerstone of limb preservation in CLI. In the field of regenerative medicine, basic research and preclinical studies have been conducted using mesenchymal stem cells (MSCs) from adult tissues, including bone marrow and adipose tissue, to overcome clinical shortcomings. Adipose-derived stem cells (ASCs) display stable growth and proliferation kinetics and can differentiate into osteogenic, chondrogenic, adipogenic, myogenic or neurogenic lineages. ASCs are readily available from autologous adipose tissue, and have significant potential for tissue repair under conditions of myocardial infarction, heart failure, hind limb ischemia, and inflammation. This review highlights some of the key reports underlining the potential of ASCs, particularly in diseases involving neovascularization.
INTRODUCTION
Regeneration of circulation is an indispensable step in the treatment of ischemic disease, organ transplantation and tissue injury repair surgery. Blood flow regeneration is dependent on blood vessel formation (revascularization) (1). In the field of regenerative medicine, several basic research and preclinical studies have been conducted using mesenchymal stem cells (MSCs) from adult tissues, including bone marrow (BM) and adipose tissue, to overcome clinical shortcomings (1-4). Although BMderived MSC (BM-MSC) have remained the primary source of stem cells for tissue engineering applications, recent studies have shown that subcutaneous adipose tissue-derived stem cells (ASCs) have a clear advantage over other sources due to ease of access and isolation from harvested tissues. ASCs display stable growth and proliferation kinetics and can differentiate into osteogenic, chondrogenic, adipogenic, myogenic or neurogenic lineages (4, 5).
Due to the high expectations in terms of utility of these attractive cell populations, recent studies have focused on the safety and efficacy of implanted ASCs in a variety of animal models. Clinical studies using ASCs have been initiated in some medical subspecialties. The differentiation potential of ASCs into vascular endothelial cells (VECs) and vascular smooth muscle cells has been reported. These cells secrete angiogenesis-related cytokines, such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), to promote angiogenesis in ischemic tissue (5, 6). Since autologous adult stem ASCs hold several advantages, such as abundant source, stable availability and simple means of collection, they are expected to present a valuable therapeutic option in revascularization and tissue repair in a variety of clinical settings (1, 4). During the past decade, preclinical studies on the safety and efficacy of ASCs have provided considerable data supporting the use of these cells in clinical applications (1, 4, 6). Recent clinical applications of ASCs have demonstrated early safety results and possibility of efficacy in patients with a range of diseases, including acute myocardial infarction, peripheral vascular disease, and skin wounds (6). In this review, the mechanisms of action and therapeutic potential of ASCs in neovascularisation are summarized, along with current preclinical data and ongoing clinical trials and their outcomes in a variety of medical fields.
CHARACTERISTICS OF CRITICAL LIMB ISCHEMIA (CLI)
CLI is diagnosed in 12% of the adult population in the U.S. Its clinical presentation varies from no symptoms to intermittent claudication, atypical leg pain, rest pain, ischemic ulcers or gangrene (7-9). CLI is a syndrome combining several peripheral artery diseases with different etiologies and pathogenesis, but with similar prognosis, high morbidity and mortality. Surgical and conservative treatment possibilities of CLI have been almost completely exhausted. These patients suffer severe blockage in arteries of the lower extremities, resulting in markedly reduced blood flow. Limb ischemia is a serious form of peripheral arterial disease (PAD), but less common than claudication. PAD is caused by atherosclerosis, the hardening and narrowing of arteries over time due to the buildup of fatty deposits denoted 'plaque'. CLI results in severe pain in the feet or toes, even while resting (10, 11). Moreover, patients with CLI have a high incidence of cardiovascular comorbidities that reflect a significant systemic atherosclerotic burden. These individuals display increased functional impairment and functional decline. Complications of poor circulation include sores and wounds that do not heal in the legs and feet. If left untreated, these complications often result in amputation of the affected limb (12, 13). 
ASCS
Recent studies have consistently shown that mesenchymal cells isolated from subcutaneous adipose tissue display multilineage developmental potential. These cells, termed 'ASCs', can be induced to differentiate into various mesenchymal lineages, including osteogenic, adipogenic, myogenic, and chondrogenic (3, 20).
ASCs express the MSC markers CD10, CD13, CD29, CD34, CD44, CD54, CD71, CD90, CD105, CD106, CD117, and STRO-1. However, the cells are negative for the hematopoietic lineage markers CD45, CD14, CD16, CD56, CD61, CD62E, CD104, and CD106, and the endothelial cell (EC) markers CD31, CD144, and von Willebrand factor. ASCs display many properties in common with MSC, such as BM-MSC (5, 21, 22). The similarities between ASCs and BM-MSC indicate that ASCs are derived from circulating BM-MSCs, which infiltrate the adipose compartment through vessel walls (23). Morphologically, the cells are fibroblast-like and preserve their shape after expansion in vitro (23). ASCs and BM-MSCs share broadly similar surface immunophenotypes. Both cell types are positive for CD10, CD13, CD90, and CD106 (3, 23). Stem cell-related surface markers, Sca1(ly-6A/E) and CD44 antigen, are expressed, but not c-kit, Lin, CD11b, CD31, CD34 or CD45, in ASCs from mice, while mouse MSCs display high levels of Sca1 and CD34, but not c-kit, Lin, CD11b, CD31 or CD459 (23). The CD34 antigen is expressed in freshly isolated human ASCs, but disappears after several days in culture (3, 24, 25). Similarly, bone marrow culture over a two-to three-week time-frame to obtain BM-MSC colonies leads to loss of CD34 antigen, which is expressed in BM , and expressed mesenchymal cell markers, smooth muscle antigens, and pericytic markers, including chondroitin sulfate proteoglycan, CD140a, and CD140b (36). Since CD140a and CD140b could not colocalize with CD34 and CD104b, it was concluded that CD34
-cells of adipose vasculature are not pericytes. The differences in surface marker expression in these studies may be explained by the stage of culture growth. Similarly, the variability of CD34 positivity is possibly a consequence of downregulation of this marker within the first few days of in vitro expansion.
Adipose tissue participates in endocrine processes by secreting cytokines and growth factors. ASCs secrete high levels of epidermal growth factor (EGF), VEGF, bFGF, keratinocyte growth factor (KGF), plateletderived growth factor (PDGF), HGF, transforming growth factor (TGF)-β, insulin-like growth factor (IGF), and brainderived neurotrophic factor (BDNF) (36). In addition, these cells secrete cytokines, such as Flt-3 ligand, granulocyte colony stimulating factor, granulocyte/macrophage colony stimulating factor, macrophage colony stimulating factor, interleukin (IL)-6, IL-7, IL-8, IL-11, IL-12, leukemia inhibitory factor (LIF), and tumor necrosis factor. This paracrine secretion of adipose tissue with ASCs may contribute to the elevated cytokine levels in cases of obesity (37). Notably, angiogenic and anti-apoptotic growth factors are secreted by ASCs at a bioactive level, and hypoxic conditions promote their secretion to a significant extent. HGF is possibly the main angiogenic factor secreted by ASCs and plays a central role in paracrine effects on ASCs. Inhibition of HGF receptors has been shown to impair the angiogenic and regenerative effects of ASCs in ischemic tissues. Moreover, knockdown of HGF reduces the ability of ASCs to promote EC proliferation and inhibits the pro-angiogenic effects of HGF in vitro (38, 39) .
Independent studies have reported data from gene microarray experiments analyzing transcriptomes of undifferentiated human ASCs and BM-MSCs (20, 40). Analysis of a 28-gene panel revealed no significant differences between the two cell types. A more comprehensive comparison using Affymetrix gene chips determined that human ASCs and MSCs share a common transcriptome (41) . The transcriptomes of MSCs and ASCs derived from different donors were shown to have a ~50% correlation coefficient, compared to an average correlation coefficient of 71% and 64% between individual donors within the ASC and MSC groups, respectively (41) . The data from mRNA transcription analysis suggest that ASCs and MSCs display distinct expression profiles with similar features. However, evaluation of the ASC and adipocyte proteome with mass spectrometry indicated that the identities of >200 proteins in both undifferentiated and adipose differentiated cells (42) (43) (44) . The human ASC proteome shares similarities with fibroblasts, MSCs and other lineages (42) (43) (44) . ASCs present a number of features that provide a key advantage for therapeutic applications, such as ease of harvest via minimally invasive liposuction and significantly greater numerical availability for harvest from adipose tissue (where culture expansion is not necessary). To date, autologous ASCs have been used in most clinical cases and human studies, which are simply derived by enzymatic and mechanical processing of adipose tissue to obtain ASC-rich cell pellets without subsequent culture. These would avoid potential harmful transformation during ex vivo culture, but the quantity of ASCs available from liposuction depends on donor age, Body Mass Index, and tissue harvest site (45) . Limited studies have focused on the qualitative differences among the activities of ASC in relation to the donor source.
NEOVASCULARIZATION
The formation of new blood vessels (neovascularization) occurs through two mechanisms, specifically, angiogenesis and asculogenesis. Angiogenesis is the process of neovascularization from preexisting blood vessels, whereas vasculogenesis refers to the generation of blood vessels from angioblast precursor cells (46, 47) . Neovascularization is essential in embryonic development, wound repair, ischemia, tumor and inflammation as a result of interactions between cells, cytokines, extracellular matrix and proteolytic enzymes. Under these physiological or pathological conditions, the process is highly regulated, turned on for brief periods and subsequently completely inhibited.
Postnatal neovascularization is thought to result exclusively from proliferation, migration, and remodeling of fully differentiated putative VECs derived from preexisting blood vessels. This adult paradigm, referred to as angiogenesis, contrasts with vasculogenesis, a term applied to the formation of embryonic blood vessels from EC progenitors or angioblasts (48) . In 1997, EC progenitors or angioblasts were isolated from human peripheral blood via magnetic bead selection on the basis of cell surface antigen expression. In vitro, these cells differentiated into VECs. These findings suggest that EC progenitors may be useful for augmenting collateral vessel growth to ischemic tissues (therapeutic angiogenesis) and delivering anti-or pro-angiogenic agents, respectively, to sites of pathologic or utilitarian angiogenesis (49) .
However, neovascularization is an essential step in the treatment of many disorders, such as cardiovascular diseases, ischemic diseases, tissue repair and 
FUNCTION AND MECHANISM OF ACTION OF ASCS IN NEOVASCULARIZATION AND TREATMENT OF CLI
Recent studies reported in vitro co-culture models using human adipose stem cells and human umbilical vein VECs, where capillary-like networks sprouting from the central lumen wall are formed in perfused tubes. It has developed an in vitro 3D model of tissue regeneration whereby human vascularized adipose tissue, human ASCs, and human umbilical vein VECs were co-cultured on 3D aqueous silk scaffolds. After two weeks of co-culture, continuous endothelial lumens formed. Furthermore, it was reported that transplantation of fat tissue with non-cultured ASCs improves long-term graft retention in an in vivo murine model. Compared to transplanted fat tissue alone, adipose tissue transplanted with non-cultured ASCs had a higher density of capillaries. These successful results may be attributed to the proangiogenic growth factors secreted by ASCs, as described previously. The studies collectively suggest a reciprocal relationship between adipose tissue remodeling and vascular regeneration. Increasing evidence has shown that ASCs can be induced to differentiate into VECs and facilitate neovascularization (24). The molecular mechanisms of ASCs in angiogenesis are summarized below (Figure 1 ).
ASCs differentiate into VECs and smooth muscle cells during neovascularisation
As pluripotent stem cells, ASCs have the potential to differentiate into VECs and vascular smooth muscle cells (24). Cells derived from ASCs can be used as building blocks to generate new vascular vessels during neovascularization.
Preadipocytes within adipose tissue depots and VECs exhibit close relationships in vivo. Earlier, Williams et al. (52) successfully isolated differentiated VECs from human adipose tissue with specific endothelial markers, including CD31, CD144 (VE-cadherin) and von Willebrand factor. Seeding these VECs onto synthetic vascular grafts improved the patency of the grafts after surgery (52) . Furthermore, in the presence of VEGF, bFGF and other growth factors, CD31
-and CD34 -cells isolated from adipose tissue showed endothelial cell phenotypes with typical phagocytosis and tube-like structure formation (4, 53). Transplantation of these cells into nude mice ischemic lesions significantly improved perfusion in damaged tissue, in which a proportion of VECs in neoformed blood vessels was obtained from ASC differentiation (4, 53). Accumulating evidence further confirmed potential differentiation into VECs. Cao et al. (54) showed that a population of CD31 This finding has been confirmed by several research groups with reproduction of both intravenous delivery of cells and intramuscular injection in the direct vicinity of ischemic injury (54, 56, 57) . Clearly, ASCs can differentiate into VECs and participate in the formation of vascular lumen under the appropriate induction conditions.
In vitro, human ASCs show a smooth muscle phenotype, indicated by the expression of smooth muscle markers, including α-smooth muscle actin, calponin, and SM22. A combination of TGF-β and PDGF-b induces commitment of ASCs into smooth muscle cells, as evident from expression of smooth muscle cell markers, including smooth muscle actin, troponin, and smooth muscle myosin heavy chain, suggesting that differentiation of ASCs into vascular smooth muscle facilitates neovascularization. A critical role of aortic carboxypeptidase-like protein in the mechanism of ASC smooth muscle differentiation was suggested, based on data from a study on preadipocytes from a murine model (58) . In addition, the finding that human ASC expression of α-smooth muscle actin and calponin is reduced in a cyclic uniaxial strain indicates that mechanical stimuli are critical in modulating the smooth muscle phenotype (59) . After injection of human ASCs into the urinary tract of immunodeficient mice in vivo, the cells persisted for up to 12 weeks and displayed smooth muscle cell morphology (60) . Moreover, transplantation of BMMSCs and endothelial precursor cells only formed capillary vessels, whereas transplanted ASCs formed large blood vessel-like structures (61) . Technological developments facilitating control of the generation and manipulation of ASC sheets may provide an effective approach to deliver smooth muscle-differentiated ASCs for genitourinary and cardiovascular regenerative procedures.
ASCs release angiogenic cytokines to promote neovascularization
Although ASCs can integrate as fully functional and differentiated VECs in vivo, they may additionally contribute to neovascularization through paracrine pathways. Adipose-derived cells secrete angiogenic cytokines, such as VEGF and HGF, which may contribute to their angiogenic properties. A number of studies have shown that ASCs secrete significant quantities of angiogenic and anti-apoptotic factors, including VEGF and HGF. These findings further encouraged a series of in vivo studies that focused on evaluating the therapeutic potential of cells based particularly on their paracrine and angiogenic effects. Intramuscular and intravenous injections of approximately 5×10
5 ASCs have been shown to functionally regenerate the vascular circulation network in ischemic hind limbs in immunocompromised mice.
The processes of neo-vascularization and angiogenesis are regulated by a number of endothelial growth factors, including VEGF and bFGF. ASCs secrete high levels of VEGF, EGF, bFGF, PDGF, KGF, HGF, TGF-β, IGF, and BDNF through autocrine or paracrine mechanisms (62) . Furthermore, pathological conditions, such as ischemia, induce the release of bFGF and VEGF from ASCs, leading to the formation of new vascular vessels. VEGF, an important angiogenic factor, promotes the proliferation and migration of VECs maintaining the integrity of vascular vessels (63) . VEGF facilitates angiogenesis synergistically with angiogenin. The growth factor affects early blood vessel formation and promotes the generation of a primitive vascular network, while angiopoietin acts on the subsequent alterations of vascular remodeling and promotes the formation of mature vessels and there is spatial structure the vascular network (63) . bFGF induces capillary growth and differentiation, leading to an increase in the number of local capillaries. IGF is another strong inducer of ASC differentiation into VECs (64).
ASC-endothelial crosstalk contributes to neovascularisation
Adipose tissue is not only an energy storage organ, but also an endocrine organ with the capability to secrete a variety of hormone-like factors, including leptin, adiponectin and resistin (38, 65) . These factors affect endothelial function and even contribute to vascular disease. VECs also secrete growth factors to regulate the growth and differentiation of adipose precursor stromal cells, affecting adipose tissue growth (38) . The collective findings indicate a reciprocal relationship between adipose tissue and VECs (66) . Recent studies have shown that adipose tissue microvascular wall ASCs have similar features to pericytes, which wrap around VECs of capillaries and venules throughout the body (36). The synergistic crosstalk between ASCs and VECs promotes neovascularization and angiogenesis. These newly formed functional blood vessels rebuild a network of blood vessels within a few weeks, facilitating improvement of vascular regeneration in organ transplant and ischemic disease (67).
THERAPEUTIC POTENTIAL OF ASCS IN VASCULAR GROWTH AND TISSUE REPAIR
In view of accumulating evidence supporting the practical utility of ASCs, their application in ischemic diseases has been highlighted in recent clinical studies, particularly as treatment for ischemic heart disease and peripheral vascular disease (68) . The number of patients with ischemic heart disease has gradually increased over the years. However, traditional treatments, such as coronary artery bypass and percutaneous transluminal coronary angioplasty, are less efficient on patients with coronary artery stenosis and insufficient blood diffusion (69, 70) . Alternative therapeutic angiogenesis treatment through introduction of ASCs has been shown to be valuable for acute coronary syndrome patients. Earlier reports indicate that intramyocardial injection of ASCs significantly ameliorates left ventricular ejection fraction and fractional shortening in an animal model of acute myocardial infarction (68) . According to the described histological effects, ASCs can increase tissue angiogenesis and reduce myocardial apoptosis and inflammatory responses.
Although ASCs have only been applied in animal models, clinical data support their potential in the treatment of ischemic lesions. In a study on human peripheral vascular disease, the subjects included six cases of Buerger's disease (thromboangiitis obliterans). After administration of autologous ASCs through intramuscular injection, the most painless walking distance, toe-brachial index, ankle-brachial index, continuous laser Doppler blood flow and ulcer healing situation were recorded in these patients (69) . Following 24 weeks of treatment, patients completely tolerated autologous ASCs, and resting pain, and other symptoms were significantly improved (70) . Recent clinical studies have shown that intramuscular injection of ASCs on the diabetic foot and arteriosclerosis obliterans have a dramatic effect. After six months of injection of ASCs, clinical manifestations included lower resting pain and improved painless walking distance with no complications. Histological assay revealed massive neovascularization and angiogenesis in ischemic tissue, suggesting an important role of ASCs in peripheral vascular revascularization (69).
CHALLENGES OF FUNCTIONAL USAGE IN NEOVASCULARIZATION
While ASCs have numerous advantages, many important scientific and medical questions remain in terms of their application, including development of largescale manufacturing methods with appropriate quality assurance, quality control to generate cells in compliance with current Good Manufacturing Practices, transformation techniques, and oncogenic risk induced by angiogenesis. Purification of ASCs is the principal problem, as there are no uniform appraisal standards. Preferably, these steps should be performed in a closed, sterile container that minimizes the risk of tissue contamination while protecting personnel from exposure to blood-borne pathogens. Cell cultures should perfomed in stirred or rotating flasks, perfused hollow fiber bioreactors or Teflon bags. It is additionally important to determine the optimal methods to store and ship ASCs, and their shelf-life. Second, the differentiation efficiency of ASCs in induction medium is not sufficiently effective for clinical usage. The identification methods for these differentiated cells are too simple to fully detect morphological or surface markers (69) . Finally, human ASCs show a capability to form tumors in immunodeficient mice after prolonged culture in vitro (71) . Therefore, long-term experiments examining the safety of ASC transplantation in appropriate animal models are warranted. Such studies should be designed to ensure that all preclinical questions are addressed before advancing to phase I studies in patients. 
